Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04614194 |
|
Recruitment Status :
Recruiting
First Posted : November 3, 2020
Last Update Posted : October 4, 2022
|
Sponsor:
University of Texas Southwestern Medical Center
Collaborators:
Eli Lilly and Company
Cancer Prevention Research Institute of Texas
Information provided by (Responsible Party):
Sangeetha Reddy, University of Texas Southwestern Medical Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | December 22, 2023 |
| Estimated Study Completion Date : | December 22, 2024 |